The cannabis market in North America continues to thrive, resulting in positive effects on stocks from the sector. With the rise of giants such as GW Pharmaceuticals plc (GWPH), Jazz Pharmaceuticals plc (JAZZ), opportunities present themself also in the micro cap areas.
This article will discuss the 5 Best Things About Cannabinoid Therapeutics Of Scisparc Ltd, (OTC: SPRCY) a clinical-stage biotechnology company that is advancing therapeutics based on cannabinoids.
1. Dr. Raphael Mechoulam
Dr. Raphael Mechoulam,also known as the founding father of cannabinoids, is a member of SciSparc's Scientific Advisory Board.
SciSparc develops cannabinoid therapies and is currently a clinical-stage company. Founded in 2004, SciSparc has since expanded its unique cannabinoid-based pipeline to include multiple therapeutic assets, based upon groundbreaking work by Raphael Mechoulam, Ph.D., Professor of Medicinal Chemistry at the Hebrew University, and a member of the company’s Scientific Advisory Board. A series of research discoveries and breakthroughs, beginning with Dr. Mechoulam’s identification of the chemical structure of THC in 1964, and subsequent mapping by researchers, globally, over many years, of the endocannabinoid system (including CB1 and CB2 receptors and the potential to exploit them as therapeutic targets in a range of indications), is the foundation on which SciSparc and others have been able to advance therapeutic assets through the clinic.
Dr. Mechoulam has laid the groundwork for a series of medical advancements in recent years, predicated on exploiting the endocannabinoid system (ECS) to treat medical conditions.
2. Commercial Production of CannAmide
SciSparc announced (Feb 9th) that it has begun commercial production in Canada of its proprietary PEA oral tablet formulation, CannAmide. The product is intended for use as an anti-inflammatory to help relieve chronic pain. The tablets are expected to be marketed to pharmacies and other retail outlets and online across Canada. Chronic pain, which this product addresses, has significant impacts on physical and mental health, family and community life, society, and the economy. Medical studies have shown that more than 100 million American individuals suffer from chronic pain, at an associated cost of about $600 billion annually, which include direct healthcare expenses, lower productivity and missed wages. In Canada, the costs to the economy due to people with chronic pain was approximately $40 billion.
3. Clinical Programs
SciSparc has several clinical stage programs for very attractive indications:
Tourette Syndrome (TS)- TS is a neuropsychiatric disorder starting in childhood. Symptoms include multiple physical and at least one vocal tic that can be disabling and associated with hyperactivity, anger control problems, sleep disorders, and obsessive-compulsive behavior. Some of the most dramatic and disabling tics include motor movements that result in self-harm or vocal tics including coprolalia or echolalia.
SciSparc completed a phase IIa clinical trial at Yale University, suggesting that the company’s treatment, SCI-110, which is a combination of THC and PEA, significantly improved symptoms over time in adult Subjects with Tourette syndrome. SciSparc intends to evaluate the efficacy, safety and tolerability of its SCI-110 in a randomized, double-blind, placebo controlled, cross-over, phase IIa clinical study.
SCI-110 for Alzheimer’s Disease and Agitation- the company recently announced it has signed an agreement with The Israeli Medical Center for Alzheimer's, to conduct a phase IIa clinical trial to evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer's disease and agitation using the Company's proprietary cannabinoid-based technology.
SCI-210 for Autism Spectrum Disorder (ASD)- the company’s treatment, SCI-210, is based on the combination of CBD and PEA for treating symptoms.
The company announced this week about an $8.15 million in private placement, to support its business plans.
5. Getting on the radar
SciSparc recently announced a series of rebranding processes. The rebranding is part of the company’s unwavering commitment of the new management, to investors, to turning the company around and steering it in the right direction. Beside the commitment of the new management to driving the company towards success, investors start to look at the stock, which went up approx. 100% in the last 6 months. The company also reviewed in an analytic research done by Aegis Capital Corp, which recommended a target price of $20.